Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Prostatic Neoplasms
Interventions
BIOLOGICAL

mRNA transfected dendritic cell

"Autologous monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.~5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration)."

DRUG

Docetaxel

Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).

Trial Locations (2)

2730

Center for Cancer Immune Therapy, Dept. of Haematology/Oncology, Copenhagen

Department of Oncology, Herlev Hospital, Herlev

All Listed Sponsors
lead

Inge Marie Svane

OTHER

NCT01446731 - Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter